Jere E. Goyan

Bioequivalence and Narrow Therapeutic Index Drugs

Every prescription written for a generic drug requires an act of faith by the prescriber that any one of the several available products will be therapeutically equivalent to the innovator (brand name) products. Concerns about this act of faith have been expressed for many years, particularly in the wake of the generic scandals that occurred in 1989–1990, and especially relative to the drugs with a narrow therapeutic range. We contend that these drugs are actually the least likely to pose problems in ensuring therapeutic equivalence, but that new criteria must be established for bioequivalence because the present system is wasteful and is stifling innovation in the industry. We propose four suggestions to the scientific and regulatory communities that we believe could assist in modifying the process such that innovation is encouraged and practitioners are reassured relative to the appropriateness of using generic drugs.

Pharmacy Education and its Impact on Practice

1986. 2. Product information. Pnulmmune (pneumococcal vaccine polyvalent). Pearl River, NY: Lederle Laboratories, November 1985. 3. LINNEMANN CC Jr, FIRST MR, SCHIFFMAN G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986;146: 1554-6. 4. Centers for Disease Control. Update: pneumococcal polysaccharide vaccine usageUnited States. MMWR 1984;33:27381. 5. BOLAN G, BROOME CV, FACKLAM RR, PLIKAYTIS BD, FRASER DW, SCHLECH WF III. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104:1-6. 6. LAWRENCE EM, EDWARDS KM, SCHIFFMAN G, THOMPSON JM, VAUGHN WK, WRIGHT PF. Pneumococcal vaccine in normal children: primary and secondary vaccination. Am J Dis Child 1983;137:846-50. 7. WEINTRUB PS, SCHIFFMAN G, ADDJEGO JE Jr, et al. Long-term follow-up and booster immunization with polyvalent pneumococcal polysaccharide in patients with sickle-cell anemia. J Pediatr 1984;105:261-3. 8. GIEBINK GS, LE CT, SCHIFFMAN G. Decline of serum antibody in splenectomized children after vaccination with pneumococcal capsular polysaccharides. J Pediatr 1984;105:576-82. 9. HILLEMAN MR, CARLSON AJ Jr, MCLEAN AA, VELLA PP, WEIBEL RE, WOODHOUR AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Inject Dis 1981; 3:S31-42. 10. SCHWARTZ JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 1982;96:208-20. II. KAFIDI KT, ROTSCHAFER JC. Bacterial vaccines for splenectomized patients. Drug Intell Clin Pharm 1988;22:192-7. 12. American College of Physicians. Pneumococcal vaccine. Ann Intern Med 1986;/04:118-20.